GCTK vs. PYPD, AKLI, SSKN, NEPH, MHUA, IINN, PAVM, TTOO, PETV, and NXGL
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include PolyPid (PYPD), Akili (AKLI), STRATA Skin Sciences (SSKN), Nephros (NEPH), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), PAVmed (PAVM), T2 Biosystems (TTOO), PetVivo (PETV), and NEXGEL (NXGL). These companies are all part of the "surgical & medical instruments" industry.
GlucoTrack (NASDAQ:GCTK) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 17.7% of GlucoTrack shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, GlucoTrack had 5 more articles in the media than PolyPid. MarketBeat recorded 8 mentions for GlucoTrack and 3 mentions for PolyPid. GlucoTrack's average media sentiment score of 0.66 beat PolyPid's score of 0.33 indicating that GlucoTrack is being referred to more favorably in the media.
GlucoTrack is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
GlucoTrack has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
GlucoTrack's return on equity of -172.38% beat PolyPid's return on equity.
PolyPid received 21 more outperform votes than GlucoTrack when rated by MarketBeat users.
Summary
PolyPid beats GlucoTrack on 7 of the 12 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
